New drug duo shows promise for Tough-to-Treat blood cancer
NCT ID NCT02537613
First seen Nov 01, 2025 · Last updated May 01, 2026 · Updated 25 times
Summary
This study tests a combination of two drugs, ibrutinib and obinutuzumab, in people with chronic lymphocytic leukemia (CLL) whose cancer has returned or not responded to prior therapy. The main goal is to check the safety of different dosing schedules. About 54 adults with CLL or a related lymphoma are taking part. The approach aims to control the disease, not cure it, and participants may need ongoing treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Duke University Medical Center
Durham, North Carolina, 27710, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
University of Rochester Wilmot Cancer Inst.
Rochester, New York, 14642, United States
Conditions
Explore the condition pages connected to this study.